Year: 2014

FDA Approval

AIT Announces Phase II Study of NOxCureCF, a Respiratory Treatment for Cystic Fibrosis Patients Using a Nitric Oxide-Base Formulation

January 7, 2014 0

AIT Announces Phase II Study of NOxCureCF, a Respiratory Treatment for Cystic Fibrosis Patients Using a Nitric Oxide-Base Formulation Enrollment in the Multicenter Trial Begins in Soroka Medical Center in Israel PR Newswire REHOVOT, Israel, January 7, 2014 REHOVOT, Israel , January 7, 2014 /PRNewswire/ — Advanced Inhalation Therapies (AIT Ltd.), an Israeli drug development company, announced today that it has begun enrollment in Israel for a multicenter, open label, Phase II clinical trial of NOxCureCF, a respiratory treatment for patients with cystic fibrosis (CF). NOxCureCF is a specialized formulation of inhaled Nitric Oxide (NO) delivered using AIT’s patented drug delivery system. David Greenberg , M.D., AIT’s Chief Medical Officer and a professor of pediatrics and infectious diseases at Soroka Medical Center in Beersheva, Israel , said: “This study, in combination with the continuation of our Phase II trial of the use of NO for treatment of infants with RSV/bronchiolitis, will allow us to substantiate and enhance the use of inhaled NO in the treatment of respiratory disease and distress.” Prof […]

Mergers & Acquisitions

RiceBran Technologies Completes Acquisition of H&N Distribution

January 7, 2014 0

RiceBran Technologies Completes Acquisition of H&N Distribution H&N Acquisition Expected to be Immediately Accretive while Driving USA Segment Sales Growth and Margin Improvement PR Newswire SCOTTSDALE, Arizona, January 7, 2014 SCOTTSDALE, Arizona , January 7, 2014 /PRNewswire/ — RiceBran Technologies (NASDAQ: RIBT) and (RIBTW) (the “Company” or “RBT”), a global leader in the production and marketing of value added products derived from rice bran, today announced the completion of the acquisition of Irving, Texas -based H&N Distribution, Inc. (“H&N”) effective January 2, 2014 . […]